Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Viking Therapeutics (VKTX NASDAQ) is developing a GLP-1/GIP dual-agonist that is similar to LLYs drug but has shown faster weight loss after 13 weeks in mid-stage trials
GLP-1 GLP-1
iASPP suppresses Gp78-mediated TMCO1 degradation to maintain Ca2 + homeostasis and control tumor growth and drug resistance
Results: Of 118 patients initiated on the GLP-1 receptor agonist, 62 (53%) resumed insulin treatment (group I), and 53 (47%) continued with GLP-1 receptor agonists or switched to oral anti-hypoglycemic agents (group II)
Reconstitute with an appropriate solvent for research use following standard laboratory practice
US$ 20.38
US$ 25.92
US$ 20.76
US$ 28.42
US$ 21.16
US$ 24.62
US$ 20.94
